Padcev (enfortumab vedotin-ejfv) Patient Assistance Program
Don’t let the high cost of brand Nectin-4-targeted antibody-drug conjugate disrupt your urothelial cancer treatment. We help eligible patients access Padcev (enfortumab vedotin-ejfv intravenous infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Padcev (enfortumab vedotin-ejfv) is FDA-approved for locally advanced or metastatic urothelial cancer in combination with pembrolizumab (Keytruda) as first-line treatment (per EV-302/KEYNOTE-A39 — established new standard of care), and as monotherapy for locally advanced or metastatic urothelial cancer after prior PD-1/PD-L1 inhibitor and platinum-containing chemotherapy (or ineligible for platinum). Antibody-drug conjugate targeting Nectin-4 — anti-Nectin-4 antibody linked to MMAE microtubule disruptor.
- Without assistance, Padcev costs commonly run approximately $12,000–$16,000 per dose (weekly on days 1 and 8 of each 21-day cycle).
- Through AffordMyPrescriptions, qualifying patients can access Padcev for a flat $69.95 per month.
- Other urothelial cancer therapies: pembrolizumab (Keytruda — combined with Padcev as new first-line standard; also monotherapy in cisplatin-ineligible PD-L1 positive), avelumab (Bavencio — maintenance after platinum chemo per JAVELIN Bladder 100), nivolumab (Opdivo — perioperative with chemo per CheckMate 274), atezolizumab (Tecentriq — historical), gemcitabine + cisplatin or gemcitabine + carboplatin (generic platinum chemo backbones), gemcitabine + paclitaxel (generic), MVAC chemotherapy. For FGFR3/2-altered urothelial cancer: erdafitinib (Balversa) per THOR. Nectin-4 testing not currently required for Padcev.
What is Padcev Prescription Assistance Program?
The Padcev Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Padcev (used for locally advanced or metastatic urothelial cancer, in combination with pembrolizumab or as monotherapy after prior therapy) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, medical oncology coordination, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing advanced bladder cancer.
At AffordMyPrescriptions, our Patient Advocates handle the entire Padcev PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation, follow up with the manufacturer’s program until approval, manage your weekly infusion cycles, and handle annual re-certification — so you never face a gap in your Padcev ADC therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Padcev enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your urothelial cancer treatment.
Pharmacy Price Comparison
- Without assistance, Padcev costs thousands of dollars per infusion at oncology centers. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this targeted urothelial cancer therapy accessible if you qualify. The table below compares typical pricing across major settings to what you'd pay with our Padcev advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Avelumab maintenance (alt) | ~$13,000/dose | Alt PD-L1 maintenance |
| Hospital oncology | ~$15,500/dose | Save substantially |
| Community oncology | ~$14,000/dose | Save substantially |
| Specialty pharmacy | ~$13,000/dose | Save substantially |
| 340B-eligible institution | ~$12,000/dose | Save substantially |
| Generic platinum chemo (alt) | ~$500/cycle | Generic chemo backbone alt |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Padcev — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Padcev Prescription Program?
The Padcev Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Padcev + Keytruda is the new first-line standard of care for advanced urothelial cancer per EV-302.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Padcev assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Padcev is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Padcev:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $12,000–$16,000/dose per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Padcev assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Padcev Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Padcev:
Padcev is an antibody-drug conjugate targeting Nectin-4, a cell adhesion molecule highly expressed in urothelial carcinoma. The anti-Nectin-4 antibody delivers the MMAE microtubule-disrupting payload selectively to tumor cells. The EV-302/KEYNOTE-A39 trial established Padcev + pembrolizumab as the new first-line standard of care for advanced urothelial cancer with dramatic improvements in PFS and OS vs platinum-based chemotherapy.
How It Works:
Urothelial cancer (bladder cancer, and ureteral/renal pelvis carcinoma) historically responded poorly to systemic chemotherapy after platinum failure, with limited durable responses to checkpoint inhibitor monotherapy in unselected patients. Nectin-4 is highly expressed on most urothelial cancers and provides a tumor-selective targeting opportunity. Enfortumab anti-Nectin-4 antibody binds Nectin-4 on tumor cells, the ADC is internalized, the cleavable linker releases the MMAE (monomethyl auristatin E) payload — MMAE binds tubulin and disrupts microtubule polymerization, causing cell cycle arrest and apoptosis. Combined with pembrolizumab’s immune activation, the combination produces dramatic and durable responses — EV-302 showed approximately doubled median overall survival vs platinum chemo, establishing the combination as the new standard.
Form and Use:
Padcev 1.25 mg/kg (max 125 mg) IV infusion on days 1 and 8 of each 21-day cycle. Combined with pembrolizumab 200 mg IV on day 1 of each cycle (or 400 mg every 6 weeks). Continue until disease progression or unacceptable toxicity. Premedication with antihistamine and corticosteroid for infusion reactions. Manage skin toxicity proactively. Periodic ophthalmologic monitoring (dry eye, blurred vision). Dose modifications for skin reactions, peripheral neuropathy, hyperglycemia, pneumonitis, ocular disorders.
Generic Availability:
No biosimilar/generic. Other urothelial cancer therapies: pembrolizumab (Keytruda — combined with Padcev as new first-line standard; also monotherapy in cisplatin-ineligible PD-L1 positive disease); avelumab (Bavencio — maintenance after platinum chemo per JAVELIN Bladder 100); nivolumab (Opdivo — perioperative with chemo per CheckMate 274 muscle-invasive disease); atezolizumab (Tecentriq — historical PD-L1 options). Standard chemotherapy backbones (generic): gemcitabine + cisplatin, gemcitabine + carboplatin, gemcitabine + paclitaxel, MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) — all generic. Sacituzumab govitecan (Trodelvy — Trop2 ADC, additional ADC option). For FGFR3/2-altered urothelial cancer: erdafitinib (Balversa) per THOR trial. Disitamab vedotin (HER2-targeting ADC in development). Bladder-preserving therapies (TURBT, intravesical BCG/chemo) and cystectomy for non-metastatic disease. NCCN bladder cancer guidelines guide treatment selection.
Warnings:
Boxed warning: serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) — sometimes fatal; mandatory patient counseling, prompt evaluation of skin reactions, withhold therapy and seek immediate dermatology consultation for severe reactions; permanent discontinuation for SJS/TEN. Other: peripheral neuropathy (sensory more than motor — monitor and dose-modify; some permanent), hyperglycemia (monitor blood glucose; can present as DKA — both with and without diabetes; counsel patients on symptoms; hold Padcev for glucose >250 mg/dL until controlled), pneumonitis (sometimes fatal), ocular disorders (dry eye, blurred vision, keratitis — monitor and refer), infusion-related reactions, embryo-fetal toxicity. Drug interactions: strong CYP3A4 inhibitors increase MMAE exposure — caution.
FAQ (Frequently Asked Questions)
How much does Padcev cost without insurance?
$12,000–$16,000 per infusion (weekly on days 1 and 8 of each 21-day cycle). Annualized cost can exceed $300,000 without assistance for combination with Keytruda. Specialty pharmacy and Patient Assistance Programs are essential.
Is Padcev considered chemotherapy?
Padcev is an antibody-drug conjugate — it delivers a chemotherapy payload (MMAE microtubule disruptor) selectively to Nectin-4-expressing tumor cells. Different from systemic chemotherapy in that the cytotoxic agent is targeted via the anti-Nectin-4 antibody, improving the therapeutic window.
Why is Padcev combined with Keytruda (pembrolizumab)?
The EV-302/KEYNOTE-A39 trial established Padcev + Keytruda as the new first-line standard of care for advanced urothelial cancer — produced dramatic and durable improvements in PFS and OS vs platinum-based chemotherapy (approximately doubling median OS). The combination of targeted ADC and checkpoint inhibitor produces synergistic activity.
How serious are the FDA boxed warnings for Padcev?
Very serious — severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis can be life-threatening. Patient counseling on early skin warning signs, prompt evaluation, and immediate discontinuation for severe reactions is essential. Most reactions occur in first cycles.
What are the other major Padcev side effects?
Peripheral neuropathy (sensory more than motor; some permanent), hyperglycemia (can present as DKA even without diabetes — monitor glucose, counsel on symptoms), pneumonitis (sometimes fatal), ocular disorders (dry eye, blurred vision, keratitis), skin reactions, infusion reactions, fatigue. Proactive monitoring and supportive care reduce most toxicities.
Take Control of Your Medication Costs
Targeted ADC therapy for advanced urothelial cancer should not be derailed by cost — Padcev + Keytruda is the new first-line standard of care. Our Padcev advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Padcev through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.